ImExHS Limited Overview
IMEXHS is a Latin America-focused, cloud-native medical imaging software and radiology services company listed in Australia. Founded by Colombian radiologists and engineers in 2012, it sells a vendor-neutral, zero-footprint suite: PACS, RIS, cardiology information system, anatomical pathology LIS and universal viewer. These are now consolidated on the Aquila+ platform, which embeds proprietary "agentic" AI workflow agents. The company also owns RIMAB SAS, a Colombian outsourced radiology and teleradiology provider that runs entirely on IMEXHS software. RIMAB generates about two-thirds of group revenue and acts as a live laboratory and data source for the AI agents. With A$29.0m FY25 revenue, A$36.8m ARR at June 2026 and about 97% recurring revenue, IMEXHS is a sub-scale but recently EBITDA-positive challenger to global PACS incumbents. It competes on cost, cloud delivery, Spanish-language local support and partner-led distribution across 18 countries. Its principal exposures are Colombian healthcare-payer liquidity and customer concentration.
What the company does
IMEXHS operates two complementary business units, which are also its two reportable segments.
-
IMEXHS Software. This unit develops and sells cloud-based medical imaging software on a subscription (SaaS) basis. The product set covers:
-
Picture Archiving and Communications System (PACS)
-
Radiology Information System (RIS)
-
Cardiology Information System (CIS)
-
Anatomical Pathology Laboratory Information System (APLIS)
-
a universal diagnostic viewer, patient portal and results-distribution tools The company describes its solutions as completely cloud-based, vendor neutral and zero footprint, with no need for locally installed software (company boilerplate, 1H FY26 announcement). Since 2025 the flagship is Aquila+, the next-generation radiology platform. Aquila v3 remains in use and is often deployed alongside Aquila+ (2026 AGM address). By 30 June 2026 the company had 569 IMEXHS Enterprise and IMEXHS Cloud installations worldwide (1H FY26 results).
-
-
Radiology Services (RIMAB SAS). This unit provides outsourced radiology, teleradiology and outpatient-clinic imaging services, mainly in Colombia. It serves hospitals, insurers (EPS) and clinic networks. RIMAB was acquired in October 2021. It operates exclusively on IMEXHS software, and AI agents built by the software business run inside RIMAB's own operation (1H FY26 Results Presentation).
Business model and revenue model
| Revenue type | Description | Share of revenue |
|---|---|---|
| Subscription SaaS (software) | Monthly recurring fees for IMEXHS Cloud (standardised, multi-tenant) and IMEXHS Enterprise (larger, customised deployments). Often priced per study or volume band. | Software was about 34% of FY25 revenue (derived: A$10.0m of A$29.0m) and 30% of 1H FY26 revenue (A$4.8m of A$16.0m) |
| Recurring services (radiology) | Contracted reading and reporting, on-site radiology department management and teleradiology. Billed monthly, frequently per-study volume. | About 66% of FY25 revenue (A$19.0m) and 70% of 1H FY26 revenue (A$11.2m) |
| One-off / implementation | Implementation fees (for example a US$50,000 one-time fee on the Zacatecas, Mexico tender), hardware and occasional perpetual or one-off sales | Small. Recurring revenue was about 97% of total in FY25 (AGM 2026 commentary). |
| Licensing via partners | Partner Programme distributors resell IMEXHS Cloud/Aquila+ | Included in software. Partners delivered 75% of software new ARR in 1H FY26. |
The company's key operating metric is Annualised Recurring Revenue (ARR), defined as monthly recurring contract revenue multiplied by twelve. A further component, "contracted but not yet billing" ARR, is reported separately. This was A$2.3m for software at 30 June 2026 (1H FY26 results).
Value chain position
IMEXHS sits at the clinical-IT application layer of the diagnostic imaging value chain:
Upstream: modality OEMs such as CT, MR and X-ray makers. Neusoft Medical is a partner (December 2021).
Downstream: radiologists and referring clinicians.
Third-party AI: algorithms are integrated on top. Gleamer's ChestView and Fracture Detection were embedded in the 2026 Mexico tender.
Through RIMAB, IMEXHS also integrates forward into the clinical service itself. That makes it unusual among PACS vendors: it is both a software vendor and a radiology service operator.
Customer types and end markets
| Customer type | Examples disclosed |
|---|---|
| Public hospitals / health systems | Colombian National Police Central Hospital (contract December 2021, renewed Q4 FY24); 20 public hospitals and clinics in Zacatecas, Mexico (May 2026 tender via distributor GOBA); Subred Integrada de Servicio de Salud Sur ESE, Bogotá |
| Private hospital groups / clinics | Hospital General de Medellín; Clínica del Occidente; Hospital Moncaleano; Hospital La Misericordia; Neurológico de México; CESAC IPS (Cartagena); Clínica El Carmelo (El Salvador) |
| Health insurers / payers (EPS) and integrated providers | Colsubsidio; Famisanar (A$1.1m ARR, March 2023); Sanitas and Colsanitas (two radiology contracts commencing Q3 FY26, about A$2.0m combined ARR) |
| Diagnostic imaging centres and outpatient networks | Diodiagnóstico (extension bringing ARR to A$490,000); DPI (Peru); Pulso Salud (Peru, A$163,000 NARR); Imágenes del Centro (Venezuela, five centres); Someditec |
| Channel partners | 47 partners across 13 LATAM countries (1H FY26), mainly Colombia (15), Mexico (9) and Ecuador (6) |
End markets are diagnostic imaging IT and radiology services in Latin America, mainly Colombia, Mexico, Peru, Ecuador and Central America. There is a residual presence in Spain, the US and Australia; boilerplate states 18 countries "including Colombia, the US and Australia".
Company's own description versus independent characterisation
Company description (paraphrased from the 2026 AGM and 1H FY26 materials): IMEXHS runs two complementary businesses with a single mission of making specialist medical imaging diagnosis more efficient and accessible. The software division builds cloud-native radiology software centred on Aquila+, now an AI-native, agentic platform. The radiology services division (RIMAB) places radiologists and reporting capacity into hospitals and runs on that software.
Independent characterisation: Economically, IMEXHS is a Colombian radiology services business (about 66–70% of revenue, thin but improving margins) attached to a small, higher-margin regional SaaS business. The software business has about A$11.8m ARR and roughly a 30% segment EBITDA margin in FY25 (AGM 2026 summary).
The investment case rests on the software unit scaling through partners and Aquila+, while RIMAB funds itself and supplies proprietary workflow data. The main structural weaknesses are:
-
exposure to Colombian payer liquidity
-
a single customer at about 33% of external FY25 revenue
-
low absolute scale against global incumbents
-
a history of equity dilution
Strategy
Stated strategy themes (latest Annual Report, AGM and 1H FY26 presentation)
-
AI-first product strategy. Embed proprietary AI agents progressively across the radiology workflow. Management's argument is that owning the full workflow, rather than a single point within it, creates durable value (CEO, 1H FY26).
-
Scale software with Aquila+ as the preferred radiology platform across LATAM. All new contracts are to deploy on Aquila+.
-
Partner-led distribution. The Partner Programme grew from 25 partners in 15 countries (2025) to 47 partners in 13 LATAM countries (1H FY26), contributing 75% of software NARR in 1H FY26.
-
Radiology services: profitability over growth. Grow opportunistically where margins are healthy and counterparties reliable. Exit sub-scale or late-paying contracts. Focus is shifting to collections and working capital.
-
Customer success. Retention, Aquila+ migration, satisfaction, upsell and cross-sell, and AI adoption (1H FY26 presentation).
-
Financial discipline. Tight cash management through 2026, debt reduction (to A$0.25m) and hard-currency pricing.
-
Commercial transformation. Tighter qualification, disciplined pipeline management and a shift toward higher-quality opportunities. Management acknowledged in 1H FY26 that this was incomplete.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Detail / target |
|---|---|---|
| FY24–FY25 | "New Value Proposition" software development programme leading to Aquila+ | Initial installs at 8 sites; on time and on budget for a second year (AGM 2026) |
| 2024–2025 | Radiology Profit Improvement Program | Pricing and productivity; RIMAB EBITDA margin improved from about 0% to 7% (FY25) |
| Apr 2025 | Equity raise | A$2.5m placement (including A$1.0m from directors) plus SPP; total A$2.6m |
| 2,025 | Partner Programme expansion | From 25 to 47 partners; SAGRILAFT anti-money-laundering and counter-terrorist-financing review of all partners completed in 1H FY26 with no exceptions |
| 28 Apr 2026 | Launch of the agentic AI platform for radiology | Five proprietary agents, rising to eight by August 2026 |
| May 2026 | Gleamer algorithm integration | ChestView and Fracture Detection in the Zacatecas deployment |
| 2,026 | Leadership refresh | New CTO, Sales Director, COO, CFO and Sales Manager |
| 2,026 | Platform engineering | Superadmin multi-tenant module; DICOM gateway scaling; lower storage, compute and engineering cost design |
| ESG / sustainability | No quantified commitments disclosed | — |
Medium-term targets and guidance
| Item | Guidance | Source |
|---|---|---|
| FY26 revenue | A$31.4m to A$33.7m (+8% to +16%) | 1H FY26 results, 28 Aug 2026 |
| FY26 underlying EBITDA | A$2.4m to A$2.7m (+48% to +66%) | 1H FY26 results |
| FY26 cash | Cash positive for the full year (AGM, May 2026; quarterly reports) | AGM 2026 |
| FY26 software | Grow software revenue faster than in FY25 | AGM 2026 |
| Phasing | More growth in revenue, earnings and cash in 2H FY26 | AGM 2026 |
| Medium-term targets (beyond FY26) | — | — |
Products & Services
Software segment
| Product / platform | Description and capabilities | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|
| Aquila+ (flagship) | Next-generation, cloud-native RIS-PACS radiology platform with embedded proprietary AI agents. Commercially live from Q1 FY25 (8 initial sites). 2026 work advanced the diagnostic viewer and scheduling modules, added a superadmin module for centralised multi-tenant operations, and strengthened DICOM gateway scaling for high-volume, multi-node environments. The company expects all new software contracts to deploy on Aquila+. | Hospitals, imaging networks, public health systems | Initial installs FY24; commercial launch Q1 FY25; agentic version April 2026 | Subscription (per study or volume tier, monthly). Exact price list not publicly disclosed. |
| Aquila+ Agentic AI Platform: proprietary AI agents | Launched 28 April 2026 with five agents covering scheduling, study prioritisation (triaging urgent and critical studies), auto-distribution of worklists, non-attendance alerts and AI-assisted report generation. By August 2026 eight agents were developed. The additional three extend into image visualisation and patient-survey workflows, plus a report-enhancement agent that incorporates patient and study context into dictated reports. Agents are trained on proprietary workflow data from RIMAB. | Aquila+ customers and RIMAB internally | April 2026 (five agents); August 2026 (eight agents) | Bundled or add-on. Not publicly disclosed. |
| Aquila v3 | Prior-generation Aquila platform, still in use and often deployed alongside Aquila+ as features migrate | Installed base | v3 (pre-2025) | Subscription |
| IMEXHS Enterprise (formerly Aquila Enterprise / Aquila Custom) | Customised, larger-scale RIS/PACS deployments that can include hardware and reporting services. Software ARR A$5.7m at end FY22. | Large hospitals, public sector, hospital groups | Ongoing | Subscription or custom contract |
| IMEXHS Cloud (formerly Aquila in the Cloud, AiC) | Standardised, multi-tenant cloud PACS/RIS for small and medium imaging centres, sold heavily through partners. 169 active contracts and A$3.5m ARR at end FY22. Tiered as IMEXHS Cloud SME and IMEXHS Cloud Enterprise. | SMEs: clinics, imaging centres, dental groups | AiC May 2020; IMEXHS Cloud Nov 2021 | Monthly subscription |
| HIRUKO™ | Original multi-tenant imaging platform underpinning AiC; also deployed in dental and teleradiology use cases (for example Radiofam at seven sites; Hunter Dental Group) | Legacy and installed base | Pre-2018 | Subscription |
| IMEXHS Universal Viewer (radiology and pathology) | Zero-footprint diagnostic viewer for DICOM radiology and digital pathology images | All customers | Upgrades through 2025–2026 | Included or subscription |
| RIS | Scheduling, worklists, reporting and billing workflow | Imaging departments | Ongoing; folded into Aquila+ | Subscription |
| PACS | Image archiving and communication; vendor-neutral archive capabilities | Imaging departments | Ongoing | Subscription or storage-based |
| CIS | Cardiology Information System | Cardiology departments | — | Subscription |
| APLIS | Anatomical Pathology Laboratory Information System | Pathology laboratories | — | Subscription |
| Patient Portal / Results Distribution Portal | Patient and referrer access to images and reports | Providers and patients | Enhancements Q1 FY25 | Included |
| IMEXHS Box | On-premises gateway or edge appliance complementing IMEXHS Cloud, enabling extensions and add-ons from the cloud | Sites needing local connectivity | Announced Dec 2021 | — |
| IMEXHS-U (IMEXHS Classroom) | Online training, installation and support academy for customers and partners outside Colombia | Partners and customers | 2020–2021 | — |
| Integrated third-party AI (Gleamer ChestView, Gleamer Fracture Detection) | Diagnostic AI algorithms embedded with Aquila+ in the Zacatecas, Mexico deployment | Public hospitals (Mexico) | May 2026 | Bundled in tender |
Radiology Services segment
| Service | Description | Target customer | Notes |
|---|---|---|---|
| Outsourced radiology department management | RIMAB runs radiology departments inside client hospitals, including radiologists, technologists and reporting | Hospital groups, EPS insurers (for example Colsubsidio, National Police Hospital) | Revenue-share structures with IMEXHS existed pre-acquisition |
| Teleradiology reading and reporting | Remote reporting for hospitals in Colombia and historically Spain | Hospitals and clinics | Uses Aquila and Aquila+ with AI agents |
| Outpatient imaging clinics | Diagnostic imaging services delivered through clinic sites | Patients via insurers | Disclosed in the 1H FY26 presentation ("outpatient clinics") |
| AI-enabled operations | Call-centre orchestration, scheduling and triage agents deployed inside RIMAB | Internal | AI orchestrates call-centre workflow (1H FY25 results) |
Financial Narrative
All figures are A$ M, year to 31 December, unless stated. Sources: annual results announcements FY21–FY25, investor presentations, Appendix 4E, and InvestSMART/Morningstar aggregator data where noted. "Underlying EBITDA" is the company's non-IFRS measure excluding FX, share-based payments, impairment and one-off items.
Income statement
Notes:
-
FY21: revenue, EBITDA (-3.0) and underlying EBITDA (-1.4) are from the FY21 results. Consolidated loss before tax was A$4.6m (FY20: A$3.5m).
-
FY22: revenue A$17.1m, EBITDA loss A$0.8m and underlying EBITDA loss A$0.1m are from the FY22 results.
-
FY23: revenue A$19,669k; EBITDA loss A$1,291k after a A$1,277k impairment; underlying EBITDA A$448k (FY23 Investor Presentation). The FY24 results later describe the FY23 comparative underlying EBITDA as A$0.2m, which is a restatement or redefinition. Net profit after abnormals of -A$4.2m is from InvestSMART/Morningstar.
-
FY23 EPS: InvestSMART shows -7.0 cents. Simply Wall St shows -A$0.11 for FY23. The difference is unresolved.
-
FY24: revenue A$26.5m (statutory A$26.4m in the Appendix 4E); net loss A$2.6m, down 41%; EPS -5.8c (Simply Wall St); EBITDA about A$0.02m (InvestSMART).
-
FY25: revenue A$29.0m; underlying EBITDA A$1.6m; after-tax loss A$2.9m (Smallcaps summary of FY25 results). EBITDA A$1.28m and EPS -2.2c (pre-abnormals) are from InvestSMART. The FY25 net loss includes the 1H FY25 A$1.7m Radiology CGU impairment. InvestSMART shows "net profit before abnormals" of -A$1.1m.
Gross profit and operating income (EBIT): not reported as headline metrics in sources reviewed. Simply Wall St reported FY24 cost of sales of A$15.5m (59% of revenue), which implies FY24 gross profit of about A$11.0m (41% gross margin, derived).
Diluted EPS: equal to basic given losses.
Margins and growth
Margins are derived from the table above. Net margins are as published by InvestSMART/Morningstar. FY25 net margin per InvestSMART is -3.9%, which uses the pre-abnormal loss. Using the after-tax loss of A$2.9m gives about -10%.
Revenue CAGR FY21–FY25: (29.0 / 13.4)^(1/4) − 1 ≈ 21.3% per year (derived). This is flattered by the RIMAB acquisition in Q4 FY21. On a like-for-like basis, FY22 growth excluding RIMAB was 7% (Q4 FY22 4C).
Balance sheet
Sources: FY21 Investor Presentation (cash A$4.2m, net assets A$16,653k); FY23 net assets A$15,726k (1H FY24 results comparative); FY24 net assets A$14.5m and cash A$2.1m (FY24 results); FY25 cash A$3.3m and debt A$0.53m (FY25 results; 1H FY26 results). Current assets and net gearing are from InvestSMART/Morningstar; negative gearing indicates net cash.
Additional balance-sheet datapoints:
-
30 June 2023: cash A$2.0m, net assets A$16.7m.
-
30 June 2024: net assets A$15.1m.
-
30 June 2025: cash A$2.5m, debt A$1.3m (1H FY25 call).
-
30 June 2026: cash A$2.0m, debt A$0.25m.
-
Net tangible assets per share fell from 16.77c (FY23) to 13.84c (FY24) (Preliminary Final Report FY24).
Goodwill and intangibles: goodwill arose on the RIMAB acquisition. It was impaired by A$1.3m (30 June 2023) and a further A$1.7m charge was taken against the Radiology CGU (1H FY25). Capitalised software development is a recurring investing outflow (A$0.6m in 1H FY26).
Net debt (derived): FY25: 0.53 − 3.3 = −A$2.8m (net cash). 30 June 2026: 0.25 − 2.0 = −A$1.75m (net cash).
Cash flow
Sources: FY21 Investor Presentation (OCF -A$2,968k; investing -A$3,386k, including RIMAB acquisition cash; financing -A$162k). FY23–FY25 are from InvestSMART/Morningstar and rounded. FY22 included a A$4.0m underwritten raise. FY25 included the A$2.5–2.6m placement and SPP.
Ratios
ROE is derived from the net loss and net assets above. Net interest cover is from InvestSMART. FY25 net debt to EBITDA is derived (−2.8 / 1.6), indicating net cash. ROA and ROIC are not meaningful given losses and are not computed. 1H FY26 receipts from customers were A$12.6m against revenue of A$16.0m, a cash-to-revenue ratio of about 79% (derived from 1H FY26 results). This illustrates elongated receivables.
Commentary on trends, inflections and drivers
Revenue. The FY21–FY22 step-up was acquisition-driven. RIMAB contributed A$1.2m in Q4 FY21 and a full year in FY22. FY22 like-for-like growth was only 7%. FY22 revenue of A$17.1m came in at the low end of guidance of A$17.0–19.0m, after the company had originally guided A$19.5–22.0m at the May 2022 AGM. That shortfall coincided with the voluntary exit of a slow-paying radiology customer on 1 July 2022.
FY23 growth of 15% was second-half weighted (2H revenue +42% versus pcp) as Famisanar and other contracts started billing. FY24 was the strongest growth year (+34%, radiology +45%), driven by repriced renewals (Colsubsidio, National Police) and new contracts.
FY25 growth slowed to 10%. Management deliberately prioritised margin and cash in radiology: it exited sub-scale or persistently late-paying contracts and accepted that these actions constrained radiology growth in 2025 (Q3 FY25 call; 1H FY25 results). FY26 guidance implies an 8–16% recovery.
Profitability inflection. Underlying EBITDA moved from a A$1.4m loss (FY21) to a A$1.6m profit (FY25), then to A$1.3m in 1H FY26 alone. FY26 guidance is A$2.4–2.7m. The drivers were:
-
RIMAB repricing, cost reduction and AI automation. RIMAB moved from near break-even to a 7% margin in FY25, then earned A$1.1m underlying EBITDA in 1H FY26 on A$11.2m revenue (about 10%, derived).
-
Corporate cost reduction. Corporate costs fell from about A$1.3m in 1H FY25 to A$0.6m in 1H FY26.
-
Directors taking fees in shares from 1 April 2022 (2022 Annual Report).
Software EBITDA has declined at the half-year level, from A$1.9m (1H FY24) to A$1.3m (1H FY25) to A$0.8m (1H FY26), even as software ARR rose. This reflects investment in Aquila+, AI agents and sales capacity, and is a key monitorable.
Statutory losses. Statutory net losses persist despite positive underlying EBITDA. The causes are recurring goodwill impairments (A$1.3m FY23; A$1.7m 1H FY25), depreciation and amortisation of capitalised software, FX losses on COP-denominated operations, share-based payments and finance costs. 1H FY26 was the first reported period with a statutory profit after tax (A$66,200, versus a A$3.0m loss in 1H FY25).
FX. Revenue is mostly generated in Colombian pesos and translated to A$. Management has shifted software pricing into hard currencies. The share of software revenue priced in USD, AUD or EUR rose from 31% (FY22) to 45% (FY23), 59% (FY24) and 69% (Q2 FY26); 73% of software ARR was in hard currencies at Q2 FY26. This reduces translation risk in the higher-margin unit.
Cash and working capital. This is the persistent weakness. FY24 revenue growth "consumed significant working capital" (FY24 results). 1H FY26 receipts trailed revenue because of Colombian healthcare-sector liquidity stress. That stress stems from delayed government payments to health insurers, and the largest customer delayed its March 2026 payment to April (1H FY26 results). The company has repeatedly relied on small equity raises: A$4.0m (2022) and A$2.5–2.6m (2025).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / services |
|---|---|---|
Software (IMEXHS Software) | IMEXHS Enterprise, IMEXHS Cloud, Aquila+/Aquila v3, AI agents, Partner Programme sales | PACS, RIS, CIS, APLIS, Universal Viewer, Patient/Results Portal, IMEXHS Box, AI agents |
Radiology Services (RIMAB plus other services) | RIMAB SAS and other IMEXHS radiology service arrangements, including joint operations | Outsourced radiology departments, teleradiology reading and reporting, outpatient imaging clinics |
Corporate (unallocated) | Listed-company costs and group overheads | — |
Revenue by Segment
| Segment | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
Software revenue (AUD Mn) | 6.4 | 7.6 | 8.9 | 10.0 |
Radiology Services revenue (AUD Mn) | 10.7 | 12.1 | 17.6 | 19.0 |
Total revenue (AUD Mn) | 17.1 | 19.7 | 26.5 | 29.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment metric | 1H FY24 | 1H FY25 | 1H FY26 |
|---|---|---|---|
Software revenue (AUD Mn) | 4.9 | 4.7 | 4.8 |
Radiology revenue (AUD Mn) | 8.9 | 9.0 | 11.2 |
Software underlying EBITDA (AUD Mn) | 1.9 | 1.3 | 0.8 |
Radiology underlying EBITDA (AUD Mn) | -0.1 | 0.3 | 1.1 |
Corporate underlying EBITDA (AUD Mn) | -1.5 | -1.3 | -0.6 |
Group underlying EBITDA (AUD Mn) | 0.3 | 0.3 | 1.3 |
Segment Margins & Growth (%)
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
Software % of group revenue | 39 | 34 | 34 |
Radiology % of group revenue | 61 | 66 | 66 |
Software YoY revenue growth (%) | 19 | 17 | 12 |
Radiology YoY revenue growth (%) | 12 | 45 | 8 |
Software underlying EBITDA margin (%) | — | — | 30 |
Radiology underlying EBITDA margin (%) | — | about 0 | 7 |
“—” = not publicly disclosed.
Revenue by Segment (FY21–FY25)
| Segment ARR | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Software ARR (AUD Mn) | 7.1 | 9.2 | 10.5 | 9.9 | 11.8 |
Radiology ARR (AUD Mn) | 13.3 | 10.5 | 14.5 | 20.1 | 23.0 |
Total ARR (AUD Mn) | 20.4 | 19.7 | 25.0 | 30.0 | 34.8 |
Group Entities
| Entity | Jurisdiction | Role |
|---|---|---|
IMEXHS Limited | Australia | ASX-listed parent |
Imaging Experts and Healthcare Services Pty Ltd | Australia | Intermediate holding company acquired in the 2018 reverse takeover |
IMEXHS Colombia (local operating company) | Colombia | Software development, sales and support. |
RIMAB SAS | Colombia | Radiology services (acquired 5 Oct 2021) |
Joint operation, National Police Hospital contract (97% interest) | Colombia | Radiology contract vehicle formed December 2024 |
Other subsidiaries (Spain, US, Mexico and others) | Various | — |
Income Statement and Margin Analysis (%)
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 13.4 | 17.1 | 19.7 | 26.5 | 29.0 |
Revenue growth YoY (%) | 23 | 28 | 15 | 34 | 10 |
Recurring revenue (AUD Mn) | 12.2 | — | — | — | — |
ARR at year end (AUD Mn) | 20.4 | 19.7 | 25.0 | 30.0 | 34.8 |
Reported EBITDA (AUD Mn) | -3.0 | -0.8 | -1.3 | 0.0 | 1.3 |
Underlying EBITDA (AUD Mn) | -1.4 | -0.1 | 0.4 | 0.5 | 1.6 |
Net profit after tax (AUD Mn) | — | — | -4.2 | -2.6 | -2.9 |
Basic EPS (A$ cents) | — | — | -7.0 | -5.8 | -2.2 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
“—” = not publicly disclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%) and Financial Ratios (x)
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Underlying EBITDA margin (%) | -10.4 | -0.6 | 2.0 | 1.9 | 5.5 |
Reported EBITDA margin (%) | -22.4 | -4.7 | -6.6 | 0.1 | 4.4 |
Net margin (%) | — | — | -14.8 | -9.9 | -3.9 |
ARR / revenue (x) | 1.52 | 1.15 | 1.27 | 1.13 | 1.20 |
Balance Sheet and Margin Analysis (%)
| Metric | FY21 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
Cash and equivalents (AUD Mn) | 4.2 | 2.4 | 2.1 | 3.3 |
Total debt (AUD Mn) | — | — | — | 0.53 |
Net assets / equity (AUD Mn) | 16.7 | 15.7 | 14.5 | — |
Total current assets (AUD Mn) | — | 8.92 | 9.26 | 13.44 |
Net gearing (%) | — | -6.7 | -6.1 | -17.2 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | -3.0 | — | 2.6 | -0.6 | 0.6 |
Investing cash flow (AUD Mn) | -3.4 | — | -2.0 | -1.0 | -1.0 |
Free cash flow, OCF plus investing (AUD Mn) | -6.4 | — | 0.6 | -1.6 | -0.4 |
Financing cash flow (AUD Mn) | -0.2 | — | — | 1.0 | 2.0 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY23 | FY24 | FY25 |
|---|---|---|---|
ROE (%), net loss / closing equity | -26.7 | -17.9 | — |
Net interest cover (x, aggregator) | -8.18 | -4.88 | -2.68 |
Net debt / underlying EBITDA (x) | — | — | -1.8 |
Revenue by Region and Revenue by Region (%)
| Region (proxy) | FY23 | FY24 | FY25 |
|---|---|---|---|
Colombia, radiology services (AUD Mn) | 12.1 | 17.6 | 19.0 |
Software, all geographies (AUD Mn) | 7.6 | 8.9 | 10.0 |
Software priced in hard currency, mainly ex-Colombia (% of software revenue) | 45 | 59 | 68 |
Date / Period Details
| Date / period | Price | Source |
|---|---|---|
Aug–Sep 2018 (post-RTO, pre-consolidation) | 0.031–0.046 range (pre 50:1 consolidation) | ASX announcement, Nov 2018 |
2 Sep 2025 | 0.220 | InvestSMART |
26 Sep 2025 | 0.235 | InvestSMART |
23 Dec 2025 | 0.370 | InvestSMART |
27 Feb 2026 | 0.410 | InvestSMART |
30 Apr 2026 | 0.390 | InvestSMART |
25 May 2026 | 0.360 | InvestSMART |
29 Jul 2026 | 0.280 | InvestSMART |
28 Aug 2026 | 0.350 | InvestSMART |
1–4 Sep 2026 | 0.350–0.355 | InvestSMART |
Share Price & Returns
| Horizon | Performance | Note |
|---|---|---|
1 year | About +32% (TradingView, as of a 2026 date); about +51–61% from A$0.22–0.235 (Sep 2025) to A$0.355 (Sep 2026) (derived) | Strong recovery after the FY25 turnaround |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Market capitalisation | About A$18m | Midpoint of A$17–19m (InvestSMART, Jul–Sep 2026) |
Net cash (30 Jun 2026) | About A$1.75m | Cash A$2.0m less debt A$0.25m |
Enterprise value | About A$16m | Derived |
EV / FY25 revenue (x) | 0.56 | 16 / 29.0 |
EV / FY26 guided revenue, midpoint A$32.6m (x) | 0.49 | Derived |
EV / FY25 underlying EBITDA (x) | 10.2 | 16 / 1.6 |
EV / FY26 guided underlying EBITDA, midpoint A$2.55m (x) | 6.3 | Derived |
EV / ARR, June 2026 (x) | 0.44 | 16 / 36.8 |
P/B | About 1.2x (estimated) | — |
Source Details
| Source | View | Note |
|---|---|---|
TradingView | Single estimate, price target A$0.35 (max and min both A$0.35) | Implies one covering analyst |
TipRanks (2025) | "Buy" with A$1.15 target | Conflicts with TradingView. The A$1.15 figure may be stale or erroneous; treat with caution. |
Simply Wall St | Revenue forecast about 18% per year over three years (as of FY24 results) | Aggregator forecast |
Capital Markets
| Item | Status |
|---|---|
Dividend history | None; IME has never paid a dividend |
Dividend policy | No dividend policy; earnings retained for growth |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt | A$0.25m at 30 June 2026 (A$0.53m at 31 Dec 2025; A$1.3m at 30 June 2025). Lender, terms and maturity not publicly disclosed in sources reviewed. Likely short-term Colombian bank facilities. |
Equity raises | 2018 A$5.5m; Oct 2019 A$10m at A$0.04 (pre-consolidation); Oct 2020 A$8.3m at A$0.03 (pre-consolidation); Aug 2022 A$4.0m underwritten; Apr–May 2025 A$2.5m placement plus SPP at A$0.35 |
Balance Sheet
| Raise | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
Equity raised (AUD Mn) | 5.5 | 10.0 | 8.8 | 0 | 4.0 | 0 | 0 | 2.6 |
Analyst Conclusions
Management guidance (28 August 2026)
-
FY26 revenue of A$31.4–33.7m (+8% to +16%)
-
FY26 underlying EBITDA of A$2.4–2.7m (+48% to +66%)
-
Cash positive for FY26 (AGM, May 2026)
-
Software revenue growth faster than FY25
-
2H weighting of revenue, earnings and cash
Implied 2H FY26: revenue A$15.4–17.7m and underlying EBITDA A$1.1–1.4m (derived, since 1H was A$16.0m and A$1.3m). The lower end implies a softer second half than the first, which is notable given the stated H2 weighting.
Consensus
There is effectively no consensus: one or two estimates at most. Simply Wall St's aggregator forecast of about 18% annual revenue growth exceeds the upper end of FY26 guidance.
Bull case
-
Contracted ARR step-up into 2H FY26 and FY27. A$2.3m of software ARR is contracted but not yet billing, Zacatecas reaches full run-rate from September 2026, and Sanitas and Colsanitas add about A$2.0m ARR from Q3 FY26. Together these could lift exit-FY26 ARR towards about A$40m (analyst estimate) against an enterprise value of about A$16m.
-
Operating leverage is now visible. Underlying EBITDA in 1H FY26 (A$1.3m) nearly equalled the whole of FY25 (A$1.6m). Corporate costs halved. RIMAB's margin has risen to about 10%. Converting EBITDA to statutory profit (1H FY26 A$66,200) can re-rate the stock from a "perennial loss-maker" multiple.
-
Differentiated AI positioning with real-world proof. Eight proprietary agents run in a live radiology operation (RIMAB) and a 20-site public deployment, combined with a partner channel that already generates 75% of NARR. This could make IMEXHS a strategic asset for an OEM or global PACS vendor seeking LATAM scale.
Bear case
-
Cash and receivables fragility. Cash fell from A$3.3m to A$2.0m in 1H FY26 despite positive EBITDA. Receipts were 79% of revenue, and one customer is about 33% of revenue. Another Colombian payment shock could force a dilutive raise at a depressed valuation; placement capacity was approved at the 2026 AGM.
-
Software growth is not yet proven repeatable. Software revenue was flat in 1H FY26 (A$4.8m versus A$4.7m). Software ARR was flat half-on-half (A$11.8m). Software segment EBITDA has declined for three consecutive halves. Management itself described smaller-deal conversion as inconsistent.
-
Structural statutory unprofitability and quality-of-earnings concerns. Underlying EBITDA excludes FX, share-based payments, impairments and credit losses. Two goodwill impairments in three years and repeated restatements of comparative underlying EBITDA and ARR (FY23 underlying EBITDA 0.4 versus 0.2; software ARR 10.5 versus 9.1) reduce confidence in adjusted metrics.
Key catalysts and monitorables (next 12 months)
| Timing (expected) | Catalyst / monitorable |
|---|---|
| Late Oct 2026 | Q3 FY26 4C: confirm billing commencement of A$1.2m contracted software ARR; Sanitas and Colsanitas go-live; Zacatecas full run-rate; receipts versus revenue |
| Late Jan 2027 | Q4 FY26 4C: full-year cash-positive delivery |
| Late Feb 2027 | FY26 results versus A$31.4–33.7m / A$2.4–2.7m guidance; statutory NPAT; any further impairment; FY27 guidance |
| Ongoing | Software NARR cadence (target: steady mid-market flow beyond tenders); partner count and productivity |
| Ongoing | Concentration: largest customer payment behaviour; Colombian payer reform under the new administration |
| Ongoing | Software segment EBITDA trend (stabilisation from A$0.8m per half) |
| Ongoing | Capital management: any use of the 7.1A placement capacity |
| Ongoing | New CFO's first reporting cycle; audit opinion on FY26 accounts |
| Ongoing | Additional AI agent commercialisation and any regulatory clearances |
Analyst verdict
IMEXHS has completed the hardest part of a micro-cap turnaround. A loss-making, acquisition-inflated imaging IT business in FY21 (underlying EBITDA −A$1.4m) has become an EBITDA-positive, about 97% recurring-revenue operator. It guides to A$2.4–2.7m underlying EBITDA in FY26 and reported its first statutory profit half in 1H FY26. The radiology arm, RIMAB, once the source of goodwill write-downs, now earns about a 10% margin and is a positive cash contributor. It also gives the company something few small PACS vendors have: a live clinical operation in which to build and prove AI workflow agents. The Zacatecas tender shows that this combination can win public-sector business against larger rivals.
At about A$16m enterprise value, the market capitalises IMEXHS at roughly 0.4–0.5x ARR and about 6x FY26 guided underlying EBITDA. That is a deep discount to any listed imaging software peer. It reflects real risks rather than neglect alone:
-
dependence on Colombian payer liquidity
-
one customer at about a third of revenue
-
a cash balance of only A$2.0m
-
a software unit whose revenue and segment EBITDA have not yet re-accelerated despite the Aquila+ investment cycle
Adjusted metrics also require scrutiny given repeated impairments and restated comparatives.
Our synthesis is that IMEXHS is a high-risk, asymmetric special situation. The next two to three quarters are decisive. Confirmation that contracted ARR converts to billing and to cash would validate the re-rating case. The tests are Zacatecas at full run-rate, Sanitas and Colsanitas live, and A$1.2m of not-yet-billing software ARR starting by end Q3 FY26, with receipts converging on revenue. A further collection shock or a dilutive raise would reset the thesis. Investors should weight cash conversion and software NARR consistency above headline underlying EBITDA when judging progress.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Independence |
|---|---|---|---|---|
Douglas (Doug) Flynn | Non-Executive Chairman | March 2020 (invested A$0.5m on joining) | About 30 years in media and ICT. Former CEO of Davies Brothers Ltd (acquired by News Corporation, 1989); Managing Director of News International plc (from 1995); leadership roles at Aegis Group and Rentokil Initial. Long-serving Chair of NEXTDC (ASX: NXT, director since Sep 2013). Senior Fellow of FINSIA; member of AICD. | — |
Dr Germán Arango | Co-Founder, CEO and Managing Director | Founder 2012; MD/CEO from Aug 2018 | Radiologist with more than 19 years' practice in Colombia; professor of neuroradiology at several Colombian universities. Co-founder and former majority owner of RIMAB. | Executive, not independent |
Damian Banks | Non-Executive Director | 22 May 2020 | Former CEO and MD of Konekt Ltd (2011–2019); earlier Westpac leadership roles. Chairman of Kip McGrath Education Centres; NED of Boom Logistics; former Chair of Vection Technologies; former director of ICSGlobal and RPM Automotive. University of Tasmania graduate. | Independent NED |
Carlos Palacio | Non-Executive Director | 28 Aug 2018 (formerly Non-Executive Chairman, 2018–2020) | — | — |
Douglas Lingard | Non-Executive Director | 6 Jan 2021 | — | — |
Executive Leadership Team
| Name | Title | Tenure | Notes |
|---|---|---|---|
Dr Germán Arango | CEO and Co-Founder | 2012–present | See above |
Fabio Carrillo | CFO | From 1 Aug 2026 | Chartered Accountant; Bachelor of Commerce (Professional Accounting), Macquarie University; 20 years in public practice in tax and business advisory. Supported by Crofts CA and a strengthened Colombian finance team. |
Reena Minhas | CFO and Company Secretary (former) | 1 Oct 2020 to 31 Jul 2026 | Resigned; orderly handover completed |
Kamille Dietrich (Automic Group) | Company Secretary | From 27 Jul 2026 | Outsourced company secretarial service |
Daniel Laverde | COO | From April 2026 | Succeeded Orlando Joven |
Orlando Joven | COO (former) | Departed 1H FY26 | — |
Mario Huyo | Sales Manager | Appointed 1H FY26 | — |
New CTO and Sales Director | — | Appointed by May 2026 | — |
Dr Jorge Marín | Co-Founder; Chief Medical Officer / Medical Director | From 2018 | — |
Andrés Vanegas | Chief Sales Officer (2018–2020 references) | — | — |
Major Shareholders
| Holder | Stake | Source / date |
|---|---|---|
Unnamed substantial holder | Decreased from 16.54% to 15.28% (on-market trading and dilution) | TipRanks summary of Form 604; date c. |
Douglas Flynn (direct and indirect) | About 3.77m direct and 0.63m indirect shares (about 8% of an estimated 54m shares, derived) | MarketIndex directors' holdings, 1 June 2026. Sold 2.18m shares off-market at A$0.41 on 5 May 2026. |
Other directors | Small; Banks participated in the April 2025 director placement (328,572 shares at A$0.35) | Appendix 3Y |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | HQ | Positioning versus IMEXHS |
|---|---|---|---|
Enterprise imaging / PACS | Philips (Philips Enterprise Imaging; legacy Carestream HCIS) | Netherlands | Global incumbent; strong in large LATAM hospitals; high price |
Enterprise imaging / PACS | GE HealthCare (Centricity / True PACS) | USA | Bundles with modalities; strong public-tender presence |
Enterprise imaging / PACS | Siemens Healthineers (syngo.via / syngo.plaza / teamplay) | Germany | Modality-linked; large hospitals |
Enterprise imaging / PACS | Fujifilm (Synapse) | Japan | Leading PACS share globally |
Enterprise imaging / PACS | Agfa HealthCare (Enterprise Imaging) | Belgium | Historic LATAM installed base |
Enterprise imaging / PACS | Sectra | Sweden | Premium enterprise imaging; limited LATAM presence |
Enterprise imaging / PACS | Intelerad | Canada | Cloud PACS for imaging centres |
Enterprise imaging / PACS | Pro Medicus (Visage 7) | Australia | ASX-listed premium enterprise viewer; US academic focus; not a LATAM rival but the key ASX valuation comparator |
Cloud PACS / SME | Regional cloud PACS vendors and open-source PACS deployments | LATAM | — |
AI radiology | Gleamer, Lunit, Aidoc, Annalise.ai | Various | Point-solution AI. Gleamer is a partner. Aidoc's orchestration platform overlaps conceptually with IMEXHS's agentic positioning. |
Radiology services (Colombia) | Hospital-owned radiology departments; national imaging chains; other teleradiology providers | Colombia | Fragmented; insurers often integrate imaging internally. |
Competitor Detail
| Metric | IMEXHS (FY25) |
|---|---|
Revenue | A$29.0m |
Revenue growth | 10% |
EBITDA margin (underlying) | 5.5% |
Recent Developments
--



